Stock Events

Stock Events

MEI Pharma 

0
45
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 23
€1.63
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

18SepExpected
Q1 2025
Next
-0.35
-0.02
0.32
0.65
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-14.43MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MMIA.STU. It's not an investment recommendation.
Amazon
2
AMZN
NVIDIA
2
NVDA
Coca-Cola
2
KO
AT&T
2
T

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
TG Therapeutics
TGTX
Mkt Cap8.31B
TG Therapeutics focuses on novel treatments for B-cell malignancies and autoimmune diseases, directly competing with MEI Pharma's cancer therapy developments.
Incyte
INCY
Mkt Cap25.91B
Incyte Corporation specializes in oncology products, including therapies for hematologic cancers, overlapping with MEI Pharma's research and development focus.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences is a major player in the development of treatments for cancer and other diseases, competing with MEI Pharma in the oncology sector.
Agios Pharmaceuticals
AGIO
Mkt Cap1.98B
Agios Pharmaceuticals focuses on cellular metabolism to develop therapies for cancer, directly competing with MEI Pharma's approach to cancer treatment.
Karyopharm Therapeutics
KPTI
Mkt Cap44.46M
Karyopharm Therapeutics focuses on nuclear export inhibitors for cancer treatment, competing in the same therapeutic area as MEI Pharma.
Novartis
NVS
Mkt Cap301.95B
Novartis is a large pharmaceutical company with a broad oncology portfolio, making it a competitor across various aspects of MEI Pharma's business.
Bristol-Myers Squibb
BMY
Mkt Cap136.88B
Bristol Myers Squibb has a diverse range of cancer treatments, including therapies that directly compete with MEI Pharma's product pipeline.

About

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
Show more...
CEO
Justin J. File
Employees
4
Country
United States
ISIN
US55279B2025
WKN
000A3D69W

Listings

XNAS
US
LITS
STU
DE
MMI0.STU
STU
DE
MMIA.STU
LSE
GB
0JW9.LSE

0 Comments

Share your thoughts

FAQ

What is MEI Pharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange MEI Pharma stocks are traded under the ticker MMIA.STU.
When is the next MEI Pharma earnings date?▼
MEI Pharma is going to release the next earnings report on September 18, 2026.
What were MEI Pharma earnings last quarter?▼
MMIA.STU earnings for the last quarter are -0.35 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is MEI Pharma revenue for the last year?▼
MEI Pharma revenue for the last year amounts to 0 EUR.
What is MEI Pharma net income for the last year?▼
MMIA.STU net income for the last year is -14.43M EUR.
Does MEI Pharma pay dividends?▼
Yes, MMIA.STU dividends are paid annual. The last dividend per share was 1.63 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does MEI Pharma have?▼
As of August 27, 2026, the company has 4 employees.
In which sector is MEI Pharma located?▼
MEI Pharma operates in the Health & Wellness sector.
When did MEI Pharma complete a stock split?▼
The last stock split for MEI Pharma was on April 17, 2023 with a ratio of 1:20.
Where is MEI Pharma headquartered?▼
MEI Pharma is headquartered in SAN DIEGO, United States.